Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.51 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | APLNR | P35414 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7200318 | 0.89 | CTSL (0.49) | APLNR | |
| SCHEMBL7200319 | 0.89 | CTSL (0.49) | APLNR | |
| SCHEMBL30910841 | 0.82 | CTSL (0.52) | APLNR | |
| SCHEMBL30627978 | 0.82 | REN (0.64) | RENAGTR2AGTR1CTSD | |
| SCHEMBL30366772 | 0.82 | MC4R (0.47) | — | |
| SCHEMBL30051262 | 0.80 | ACE (0.55) | — | |
| SCHEMBL31050545 | 0.80 | MC4R (0.53) | APLNR | |
| SCHEMBL30015333 | 0.79 | REN (0.53) | RENAGTR2 | |
| SCHEMBL29399621 | 0.77 | REN (0.67) | RENLNPEPAGTR2AGTR1 | |
| SCHEMBL31362671 | 0.76 | OPRM1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043473-A1 | NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES | PHOENIX NEST INC. | 2024-02-08 | — | — | US | claimed |
| WO-2022173827-A1 | NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES | PHOENIX NEST INC. (US) | 2022-08-18 | — | — | WO | claimed |
| US-12522642-B2 | Recombinant protein comprising multiple multi-peptide sets, pharmaceutical composition comprising the recombinant protein, and method for preparing the recombinant protein | CHIEN HUNG CHIEN (TW) | 2026-01-13 | — | — | US | disclosed |
| US-20250360156-A1 | SYNERGISTIC COMBINATION OF NAD+ AND THERAPEUTIC PEPTIDES DELIVERED VIA IONTOPHORESIS FOR ENHANCED AND PROLONGED REGENERATIVE EFFECTS | ANDREWS NICHOLAS JEROME (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250312463-A1 | AUGMENTED PEPTIDE COMPOSITIONS AND METHODS | Neo7Bioscience, Inc. (US) | 2025-10-09 | — | — | US | disclosed |
| US-20240043473-A1 | NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES | PHOENIX NEST INC. | 2024-02-08 | — | — | US | disclosed |
| US-20230323401-A1 | METHODS AND COMPOSITIONS FOR GENOME EDITING | LIGANDAL INC (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322886-A1 | RECOMBINANT PROTEIN COMPRISING MULTIPLE MULTI-PEPTIDE SETS, PHARMACEUTICAL COMPOSITION COMPRISING THE RECOMBINANT PROTEIN, AND METHOD FOR PREPARING THE RECOMBINANT PROTEIN | CHIEN HUNG CHIEN (TW) | 2023-10-12 | — | — | US | disclosed |
| US-20230322872-A1 | RECOMBINANT PROTEIN COMPRISING MULTIPLE MULTI-PEPTIDE SETS, PHARMACEUTICAL COMPOSITION COMPRISING THE RECOMBINANT PROTEIN, AND METHOD FOR PREPARING THE RECOMBINANT PROTEIN | CHIEN HUNG CHIEN (TW) | 2023-10-12 | — | — | US | disclosed |
| US-20230059921-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTICALLY-RESPONSIVE LIGAND-TARGETED DELIVERY OF THERAPEUTIC AGENTS | LIGANDAL INC (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2022173827-A1 | NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES | PHOENIX NEST INC. (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230323401-A1 | METHODS AND COMPOSITIONS FOR GENOME EDITING | FEN1, DNASE1, DCLRE1B | REN 3069/4885LNPEP 252/4885AGTR2 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.